Temporal stability of the Unified Dyskinesia Rating Scale
Identifieur interne : 001206 ( Main/Corpus ); précédent : 001205; suivant : 001207Temporal stability of the Unified Dyskinesia Rating Scale
Auteurs : Christopher G. Goetz ; Glenn T. Stebbins ; Ad Theeuwes ; Fabrizio Stocchi ; Joaquim J. Ferreira ; Serge Van De Witte ; Juliana BronzovaSource :
- Movement Disorders [ 0885-3185 ] ; 2011-12.
English descriptors
Abstract
Background:: The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established. Methods:: Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF). Results:: For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (P < .0005) to 0.513 (P < .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (P < .0005) to 0.703 (P < .0005). Conclusions:: The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23931
Links to Exploration step
ISTEX:B5B36CF0A62FC02C17484BF4C57616831698200CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Temporal stability of the Unified Dyskinesia Rating Scale</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Theeuwes, Ad" sort="Theeuwes, Ad" uniqKey="Theeuwes A" first="Ad" last="Theeuwes">Ad Theeuwes</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Van De Witte, Serge" sort="Van De Witte, Serge" uniqKey="Van De Witte S" first="Serge" last="Van De Witte">Serge Van De Witte</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B5B36CF0A62FC02C17484BF4C57616831698200C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23931</idno><idno type="url">https://api.istex.fr/document/B5B36CF0A62FC02C17484BF4C57616831698200C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001206</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Temporal stability of the Unified Dyskinesia Rating Scale</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Theeuwes, Ad" sort="Theeuwes, Ad" uniqKey="Theeuwes A" first="Ad" last="Theeuwes">Ad Theeuwes</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation><mods:affiliation>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Van De Witte, Serge" sort="Van De Witte, Serge" uniqKey="Van De Witte S" first="Serge" last="Van De Witte">Serge Van De Witte</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Bronzova, Juliana" sort="Bronzova, Juliana" uniqKey="Bronzova J" first="Juliana" last="Bronzova">Juliana Bronzova</name><affiliation><mods:affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12">2011-12</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2556">2556</biblScope><biblScope unit="page" to="2559">2559</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B5B36CF0A62FC02C17484BF4C57616831698200C</idno><idno type="DOI">10.1002/mds.23931</idno><idno type="ArticleID">MDS23931</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinimetrics</term><term>dyskinesia rating scales</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:: The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established. Methods:: Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF). Results:: For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (P < .0005) to 0.513 (P < .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (P < .0005) to 0.703 (P < .0005). Conclusions:: The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Ad Theeuwes MSc</name><affiliations><json:string>Abbott Healthcare Products BV, Weesp, The Netherlands</json:string></affiliations></json:item><json:item><name>Fabrizio Stocchi MD, PhD</name><affiliations><json:string>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</json:string></affiliations></json:item><json:item><name>Joaquim J. Ferreira MD, PhD</name><affiliations><json:string>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Serge van de Witte PhD</name><affiliations><json:string>Abbott Healthcare Products BV, Weesp, The Netherlands</json:string></affiliations></json:item><json:item><name>Juliana Bronzova MD, DSc</name><affiliations><json:string>Abbott Healthcare Products BV, Weesp, The Netherlands</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia rating scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinimetrics</value></json:item></subject><articleId><json:string>MDS23931</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background:: The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established. Methods:: Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF). Results:: For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (P > .0005) to 0.513 (P > .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (P > .0005) to 0.703 (P > .0005). Conclusions:: The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1655</abstractCharCount><pdfWordCount>12490</pdfWordCount><pdfCharCount>83283</pdfCharCount><pdfPageCount>20</pdfPageCount><abstractWordCount>260</abstractWordCount></qualityIndicators><title>Temporal stability of the Unified Dyskinesia Rating Scale</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>2559</last><first>2556</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23931</json:string></doi><id>B5B36CF0A62FC02C17484BF4C57616831698200C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/B5B36CF0A62FC02C17484BF4C57616831698200C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/B5B36CF0A62FC02C17484BF4C57616831698200C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B5B36CF0A62FC02C17484BF4C57616831698200C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Temporal stability of the Unified Dyskinesia Rating Scale</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Christopher G. Goetz was engaged at an hourly‐payment rate by Solvay Pharmaceuticals, later by Abbott Pharameuticals, to act as a centralized rater for a clinical trial but did not participate in the clinical trial itself. Fabrizio Stocchi and Joaquim J. Ferreira were the principal investigators of the clinical trial and received funds from Solvay and later Abbott to conduct the trial. Serge van de Witte and Juliana Bronzova are employees of Abbott Healthcare Products, and Ad Theeuwes is a former employee of Abbott Healthcare Products.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Temporal stability of the Unified Dyskinesia Rating Scale</title><author><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Suite 755 West Harrison Street, Chicago, IL 60612 USA</p></note><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Ad</forename><surname>Theeuwes</surname></persName><roleName type="degree">MSc</roleName><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Stocchi</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</affiliation></author><author><persName><forename type="first">Joaquim J.</forename><surname>Ferreira</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</affiliation></author><author><persName><forename type="first">Serge</forename><surname>van de Witte</surname></persName><roleName type="degree">PhD</roleName><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation></author><author><persName><forename type="first">Juliana</forename><surname>Bronzova</surname></persName><roleName type="degree">MD, DSc</roleName><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-12"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2556">2556</biblScope><biblScope unit="page" to="2559">2559</biblScope></imprint></monogr><idno type="istex">B5B36CF0A62FC02C17484BF4C57616831698200C</idno><idno type="DOI">10.1002/mds.23931</idno><idno type="ArticleID">MDS23931</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:: The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established. Methods:: Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF). Results:: For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (P < .0005) to 0.513 (P < .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (P < .0005) to 0.703 (P < .0005). Conclusions:: The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>dyskinesia rating scales</term></item><item><term>clinimetrics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-04-13">Received</change><change when="2011-08-02">Registration</change><change when="2011-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/B5B36CF0A62FC02C17484BF4C57616831698200C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v26.14</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2011-12">December 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="240" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23931</doi><idGroup><id type="unit" value="MDS23931"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-04-13"></event><event type="manuscriptRevised" date="2011-07-19"></event><event type="manuscriptAccepted" date="2011-08-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-09-13"></event><event type="publishedOnlineFinalForm" date="2011-12-14"></event><event type="firstOnline" date="2011-09-13"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2556</numbering><numbering type="pageLast">2559</numbering></numberingGroup><correspondenceTo>Suite 755 West Harrison Street, Chicago, IL 60612 USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23931.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="7"></count><count type="wordTotal" number="2919"></count></countGroup><titleGroup><title type="main" xml:lang="en">Temporal stability of the Unified Dyskinesia Rating Scale<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Temporal Stability of the UDysRS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName><contactDetails><email>cgoetz@rush.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Ad</givenNames><familyName>Theeuwes</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Fabrizio</givenNames><familyName>Stocchi</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Joaquim J.</givenNames><familyName>Ferreira</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Serge</givenNames><familyName>van de Witte</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Juliana</givenNames><familyName>Bronzova</familyName><degrees>MD, DSc</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NL" type="organization"><unparsedAffiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="PT" type="organization"><unparsedAffiliation>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dyskinesia rating scales</keyword><keyword xml:id="kwd3">clinimetrics</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF).</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (<i>P</i> < .0005) to 0.513 (<i>P</i> < .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (<i>P</i> < .0005) to 0.703 (<i>P</i> < .0005).</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Christopher G. Goetz was engaged at an hourly‐payment rate by Solvay Pharmaceuticals, later by Abbott Pharameuticals, to act as a centralized rater for a clinical trial but did not participate in the clinical trial itself. Fabrizio Stocchi and Joaquim J. Ferreira were the principal investigators of the clinical trial and received funds from Solvay and later Abbott to conduct the trial. Serge van de Witte and Juliana Bronzova are employees of Abbott Healthcare Products, and Ad Theeuwes is a former employee of Abbott Healthcare Products.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Temporal stability of the Unified Dyskinesia Rating Scale</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Temporal Stability of the UDysRS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Temporal stability of the Unified Dyskinesia Rating Scale</title></titleInfo><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><description>Correspondence: Suite 755 West Harrison Street, Chicago, IL 60612 USA</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ad</namePart><namePart type="family">Theeuwes</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Stocchi</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Roma, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joaquim J.</namePart><namePart type="family">Ferreira</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Serge</namePart><namePart type="family">van de Witte</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juliana</namePart><namePart type="family">Bronzova</namePart><namePart type="termsOfAddress">MD, DSc</namePart><affiliation>Abbott Healthcare Products BV, Weesp, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-12</dateIssued><dateCaptured encoding="w3cdtf">2011-04-13</dateCaptured><dateValid encoding="w3cdtf">2011-08-02</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">7</extent><extent unit="words">2919</extent></physicalDescription><abstract lang="en">Background:: The objective of this study was to establish temporal stability characteristics for objective components of the Unified Dyskinesia Rating Scale (UDysRS). The UDysRS has strong internal consistency and a reliable factor structure, but the important issue of temporal stability has not been established. Methods:: Using intraclass correlation coefficient (ICC) analyses, we examined UDysRS temporal stability for the objective scale components (Part III and IV) over an 8‐hour observation period. We assessed ICCs for the single centralized rater, the on‐site raters, and the agreement between the single centralized rater and the on‐site raters. Kappa statistic assessed agreement between the single centralized and on‐site raters for clinical state (ON vs OFF). Results:: For both the single centralized rater and the on‐site raters, there was high temporal stability of the UDysRS Part III, Part IV, and Total Objective UDysRS in both ON and OFF states, with ICCs ranging from 0.822 (P < .0005) to 0.513 (P < .013). The agreement between the 2 rating techniques (centralized vs on‐site) was significant for ON and OFF ratings of Part III, Part IV, and Total Objective UDysRS, ranging from 0.821 (P < .0005) to 0.703 (P < .0005). Conclusions:: The UDysRS is highly stable for ON and OFF. Our data suggest that a single UDysRS evaluation for ON and for OFF states is highly representative of that state regardless of time. Likewise, if appropriate protocols need to assess dyskinesia in a field or community setting, the UDysRS can be filmed without an on‐site rater and rated centrally with retained validity. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Christopher G. Goetz was engaged at an hourly‐payment rate by Solvay Pharmaceuticals, later by Abbott Pharameuticals, to act as a centralized rater for a clinical trial but did not participate in the clinical trial itself. Fabrizio Stocchi and Joaquim J. Ferreira were the principal investigators of the clinical trial and received funds from Solvay and later Abbott to conduct the trial. Serge van de Witte and Juliana Bronzova are employees of Abbott Healthcare Products, and Ad Theeuwes is a former employee of Abbott Healthcare Products.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>dyskinesia rating scales</topic><topic>clinimetrics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2556</start><end>2559</end><total>4</total></extent></part></relatedItem><identifier type="istex">B5B36CF0A62FC02C17484BF4C57616831698200C</identifier><identifier type="DOI">10.1002/mds.23931</identifier><identifier type="ArticleID">MDS23931</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001206 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001206 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:B5B36CF0A62FC02C17484BF4C57616831698200C
|texte= Temporal stability of the Unified Dyskinesia Rating Scale
}}
| This area was generated with Dilib version V0.6.23. |  |